Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 17/20 | 0.72 |
| ▸ | METAP1 | P53582 | 8/20 | 0.72 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.47 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6487076 | 1.00 | METAP2 (0.72) | METAP2METAP1CTSSNPY5RMMP13 | |
| SCHEMBL6485254 | 0.90 | METAP2 (0.76) | METAP2METAP1CTSS | |
| SCHEMBL6485560 | 0.87 | METAP2 (0.69) | METAP2METAP1CTSS | |
| SCHEMBL6485633 | 0.85 | METAP2 (0.72) | METAP2METAP1 | |
| SCHEMBL6477214 | 0.85 | METAP2 (0.66) | METAP2METAP1 | |
| SCHEMBL6485586 | 0.84 | METAP2 (0.71) | METAP2METAP1 | |
| SCHEMBL6488421 | 0.84 | METAP2 (1.00) | METAP2METAP1CTSS | |
| SCHEMBL7356285 | 0.84 | METAP2 (0.71) | METAP2METAP1CTSSNPY5R | |
| SCHEMBL6484295 | 0.83 | METAP2 (0.69) | METAP2METAP1 | |
| SCHEMBL6489581 | 0.83 | METAP2 (0.73) | METAP2METAP1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | METAP2 1/4885METAP1 2/4885CTSS 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.